Cargando…

Ligand-directed labeling of opioid receptors for covalent attachment of fluorophores or small-molecule probes

This protocol describes endogenous labeling of opioid receptors (ORs) using a ligand-directed reagent, naltrexamine-acylimidazole compounds (NAI-X). NAI acts by guiding and permanently tagging a small-molecule reporter (X)—such as fluorophores or biotin—to ORs. Here we detail syntheses and uses of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Adoff, Hayden, Halls, Victoria S., Holland, Emily, Lobingier, Braden, Arttamangkul, Seksiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154970/
https://www.ncbi.nlm.nih.gov/pubmed/37104091
http://dx.doi.org/10.1016/j.xpro.2023.102231
Descripción
Sumario:This protocol describes endogenous labeling of opioid receptors (ORs) using a ligand-directed reagent, naltrexamine-acylimidazole compounds (NAI-X). NAI acts by guiding and permanently tagging a small-molecule reporter (X)—such as fluorophores or biotin—to ORs. Here we detail syntheses and uses of NAI-X for OR visualization and functional studies. The NAI-X compounds overcome long-standing challenges in mapping and tracking endogenous ORs as the labeling can be done in situ with live tissues or cultured cells. For complete details on the use and execution of this protocol, please refer to Arttamangkul et al.(1)(,)(2)